Every Form 4 that iRadimed Corporation (IRMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRMD filings page.
IRADIMED CORP (IRMD) director Monty K. Allen reported selling a total of 1,419 shares of common stock on September 3, 2026 in open-market or private transactions. The sales included 1,014 shares at a weighted average sale price of $86.44 per share (from trades between $86.36 and $86.54) and 405 shares at $86.35 per share. The filing states these transactions were not made under a Rule 10b5-1 trading plan and does not report Mr. Allen's remaining share holdings.
IRADIMED CORP CFO John Glenn reported routine equity compensation activity. On June 20, 2026, he exercised 5,796 restricted stock units into the same number of common shares. To cover related tax obligations, 2,319 shares of common stock were disposed of as a tax-withholding transaction, not an open-market sale. After these entries, he directly holds 11,937 shares of IRADIMED common stock.
IRADIMED CORP director Hilda Frederique Scharen-Guivel sold 3,000 shares of Common Stock in open-market transactions at $95.00 per share. The sales occurred on June 4, 2026. Footnotes state that the shares she continues to hold were acquired through the vesting and settlement of restricted stock units granted for her board service.
IRADIMED CORP director and CEO Roger E. Susi reported indirect open‑market sales of 2,500 shares of Common Stock through the Phillip Susi 2008 Dynasty Trust. The shares were sold on June 1, 2026 in multiple trades at weighted average prices between $88.68 and $91.91, under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 5, 2025.
After these sales, the Phillip Susi 2008 Dynasty Trust held 2,162,500 shares. Separate indirect holdings reported include 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust and 162,950 shares held by the Roger E. Susi Revocable Trust. Susi disclaims beneficial ownership beyond his pecuniary interest in these trust‑held shares.
IRADIMED CORP director and CEO Roger E. Susi reported that the Phillip Susi 2008 Dynasty Trust, an entity associated with him, sold a total of 7,500 shares of common stock in open-market transactions on May 26–27, 2026.
The reported weighted-average sale prices ranged from about $91.85 to $92.93 per share across four trades. After these sales, the trust continued to hold 2,165,000 shares of IRADIMED common stock indirectly. All transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on November 5, 2025, indicating they were pre-planned rather than discretionary.
IRADIMED CORP director and CEO Roger E. Susi, through the Phillip Susi 2008 Dynasty Trust, reported open‑market sales of 7,500 shares of Common Stock over May 18–19, 2026. Reported sale prices ranged from about $85.95 to $88.65 per share.
The filing notes these sales were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted by the reporting person on November 5, 2025, indicating the timing was set in advance. The trust continues to hold a substantial indirect stake in IRADIMED after these transactions, while Susi disclaims beneficial ownership beyond his pecuniary interest.
IRADIMED CORP director and CEO Roger E. Susi reported pre-planned insider sales of common stock. Entities associated with him, specifically the Phillip Susi 2008 Dynasty Trust, sold a total of 7,500 shares of IRMD common stock in open-market transactions on May 11 and May 12 under a Rule 10b5-1 trading plan adopted on November 5, 2025. The sales occurred at weighted-average prices around the mid-$80s per share, with execution ranges from $83.11 to $86.00. The filing also records indirect holdings of 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust and 162,950 shares by the Roger E. Susi Revocable Trust as of May 11, reflecting additional indirect ownership structures.
IRADIMED CORP director and CEO Roger E. Susi reported indirect open‑market sales of a total of 7,500 shares of common stock by the Phillip Susi 2008 Dynasty Trust on May 4–5, 2026, at prices including $87.31 and $83.78 per share.
The transactions were carried out under a Rule 10b5-1 trading plan adopted on November 5, 2025, indicating they were pre‑scheduled. The filing also reflects indirect holdings through additional family trusts, and Susi disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
IRADIMED CORP insider reporting person Roger E. Susi, who serves as CEO, President, Chairman and a 10% owner, reported indirect open-market sales of Common Stock through the Phillip Susi 2008 Dynasty Trust.
Across seven transactions on April 27–28, 2026, that trust sold a total of 7,500 shares at weighted average prices ranging from about $84 to $90 per share, leaving 2,197,905 shares held indirectly by that trust. Additional indirect holdings include 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust and 162,950 shares by the Roger E. Susi Revocable Trust as of April 27, 2026.
The filing notes that these sales were made under a Rule 10b5-1 trading plan adopted on November 5, 2025, indicating a pre-arranged program rather than discretionary timing. It also states that the reporting person disclaims beneficial ownership of the reported securities except to the extent of any pecuniary interest.
IRADIMED CORP insider Roger E. Susi, through the Phillip Susi 2008 Dynasty Trust, reported open‑market sales of 7,500 shares of common stock on April 20–21, 2026. Reported sale prices include $93.90, $93.14, $92.66, $91.65, $90.60 and $89.73 per share.
The filing notes these transactions were made under a Rule 10b5‑1 trading plan adopted on November 5, 2025, indicating they were pre‑scheduled. Post‑transaction line items show the trusts continuing to hold sizable indirect positions, with balances ranging from hundreds of thousands to over two million shares.
IRADIMED CORP director and CEO Roger E. Susi reported indirect open-market sales of 7,500 shares of common stock on April 13–14, 2026. The transactions were executed by the Phillip Susi 2008 Dynasty Trust at weighted average prices around $92–$94 per share under a Rule 10b5-1 trading plan adopted on November 5, 2025. Following these sales, the Phillip Susi 2008 Dynasty Trust held 2,210,000 shares indirectly, while separate indirect holdings reported include 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust as of April 13, 2026.
IRADIMED CORP insider Roger E. Susi, CEO, President and Chairman, reported that the Phillip Susi 2008 Dynasty Trust sold a total of 7,500 shares of common stock in open-market transactions on April 6–7. Reported sale prices ranged from $94.36 to $96.78 per share, and the filing notes these trades were made under a Rule 10b5-1 trading plan adopted on November 5, 2025.
Following these sales, the Phillip Susi 2008 Dynasty Trust holds 2,217,500 shares. The filing also reports indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, and states that Susi disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
IRADIMED CORP director and CEO-related trust reports routine open-market sales of common stock. The Phillip Susi 2008 Dynasty Trust sold a total of 7,500 shares of IRMD on March 30, 2026 in three transactions at weighted average prices of $94.81, $95.66 and $96.53 per share. After these trades, the Dynasty Trust holds 2,225,000 shares, while additional indirect holdings reported include 162,950 shares in the Roger E. Susi Revocable Trust and 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan, and the reporting person disclaims beneficial ownership of the securities beyond his pecuniary interest.
IRADIMED CORP director and CEO Roger E. Susi reported open-market sales of 7,500 shares of Common Stock, executed indirectly through the Phillip Susi 2008 Dynasty Trust. The sales occurred on March 23–24, 2026 at prices around $100 per share, including transactions at $99.58, $100.03, $100.71, $100.70 and $102.02 per share.
A footnote states these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating a scheduled selling program rather than ad hoc market timing. After the transactions, the Phillip Susi 2008 Dynasty Trust held 2,232,500 shares, while other indirect holdings included 2,062,500 shares in the Matthew Susi 2008 Dynasty Trust and 162,950 shares in the Roger E. Susi Revocable Trust as of March 23, 2026. Susi disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
IRADIMED CORP director and CEO Roger E. Susi reported indirect open-market sales of company common stock through the Phillip Susi 2008 Dynasty Trust. On March 16–17, 2026, the trust sold a total of 7,500 shares at weighted average prices of about $101.18, $101.68 and $102.43 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating they were scheduled in advance. After these transactions, the Phillip Susi 2008 Dynasty Trust holds 2,240,000 shares. The filing also lists additional indirect holdings of 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust, with Susi disclaiming beneficial ownership beyond his pecuniary interest.
IRADIMED CORP’s CEO, president and chairman Roger E. Susi reported indirect open‑market sales of company common stock by the Phillip Susi 2008 Dynasty Trust. The trust sold 5,000 shares on March 9, 2026 at a weighted average price of $100.04 per share and 2,500 shares on March 10, 2026 at a weighted average price of $100.11 per share. These sales were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 5, 2025. Following the March 10 sale, the dynasty trust held 2,247,500 shares indirectly, and additional indirect holdings are reported for the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
IRADIMED CORP director and CEO Roger E. Susi reported planned insider sales of company stock through a family trust. A total of 7,500 shares of common stock were sold on March 6, 2026 by the Phillip Susi 2008 Dynasty Trust in open-market transactions at weighted average prices of $98.25 and $99.12 per share, under a Rule 10b5-1 trading plan adopted on November 5, 2025. Following these sales, indirect holdings reported for related trusts included 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust.
IRADIMED CORP Chief Commercial Officer Jeff Chiprin reported an equity award of 1,150 restricted stock units (RSUs). These RSUs were granted under Iradimed Corporation's 2023 Equity Incentive Plan and carry no cash exercise price.
The RSUs convert into common stock on a one-for-one basis. They vest in three equal annual installments beginning on December 7, 2026, and upon each vesting date Mr. Chiprin will receive the corresponding number of common shares.
Iradimed Corp's chief financial officer John Glenn received a grant of 8,907 restricted stock units (RSUs). The RSUs were awarded under Iradimed Corporation's 2023 Equity Incentive Plan and convert into common stock on a one-for-one basis.
The award vests in three equal annual installments beginning on December 7, 2026. After vesting, Glenn will receive one share of common stock for each vested RSU, and he currently holds 8,907 RSUs directly following this grant.
IRADIMED CORP director Monty K. Allen reported an open-market sale of company stock. On 02/13/2026, he sold 1,000 shares of common stock in multiple trades at a weighted average price of $100.2563 per share. After this transaction, he directly owned 21,000 shares of IRADIMED CORP common stock.
IRADIMED CORP insider activity centers on trust-managed share sales linked to CEO Roger E. Susi. On January 26, 2026, the Phillip Susi 2008 Dynasty Trust sold 4,339 common shares at a weighted average price of $100.54 and 661 shares at $101.38, both under a pre-established Rule 10b5-1 trading plan adopted on June 16, 2025.
After these sales, that trust held 2,262,500 shares. The filing also lists 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, with Susi expressly disclaiming beneficial ownership of the latter beyond his pecuniary interest.
IRADIMED CORP insider activity: A trust associated with CEO, President and Chairman Roger E. Susi reported three planned sales of common stock on January 20, 2026 under a Rule 10b5-1 trading plan adopted on June 16, 2025. The Phillip Susi 2008 Dynasty Trust sold 2,129 shares at a weighted average price of $101.03, 1,074 shares at $102.03, and 1,797 shares at $102.70. After these transactions, that trust held 2,267,500 shares of IRADIMED common stock. The filing also shows indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, with the reporting person disclaiming beneficial ownership beyond his pecuniary interest.
IRADIMED Corp insider trusts reported planned stock sales. Trusts associated with CEO, President and Chairman Roger E. Susi sold a total of 5,000 shares of IRADIMED common stock on January 12, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025.
The Phillip Susi 2008 Dynasty Trust sold 4,888 shares at a weighted average price of $97.43 and 112 shares at $98.15, leaving it with 2,272,500 shares indirectly reported. Additional indirect holdings reported include 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, with beneficial ownership disclaimed except to the extent of pecuniary interest.
IRADIMED Corporation insider activity centered on trust-held shares linked to its CEO. A trust associated with CEO, President and Chairman Roger E. Susi, the Phillip Susi 2008 Dynasty Trust, sold a total of 5,000 shares of IRADIMED common stock on January 5, 2026 in multiple transactions coded as open-market sales.
The reported weighted average sale prices ranged from $95.10 to $99.48, with underlying trade price ranges disclosed between $94.55 and $99.60, all under a Rule 10b5-1 trading plan adopted on June 16, 2025. After these sales, the Phillip Susi 2008 Dynasty Trust held 2,277,500 shares, while additional indirect holdings reported for Roger E. Susi were 162,950 shares through the Roger E. Susi Revocable Trust and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust.
Iradimed Corp’s CEO, president, chairman and 10% owner Roger E. Susi reported insider sales of the company’s common stock. On 12/15/2025, a Rule 10b5-1 trading plan arranged for the sale of 4,269 shares at a weighted average price of $96.68 and 731 shares at a weighted average price of $97.13, both through the Phillip Susi 2008 Dynasty Trust.
After these transactions, the form reports indirect beneficial ownership of 2,292,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust. The filing notes the trades were executed under a pre-established Rule 10b5-1 trading plan adopted on June 16, 2025, and that beneficial ownership of certain securities is disclaimed except to the extent of pecuniary interest.
Iradimed Corporation director Hilda Scharen-Guivel reported receiving 1,026 restricted stock units on December 11, 2025 under the company’s 2023 Equity Incentive Plan. The units were granted at a price of $0 and each restricted stock unit converts into one share of common stock.
The restricted stock units vest in two equal annual installments beginning on December 11, 2026, spreading the award over two years. After this grant, she beneficially owns 1,932 derivative securities, held directly.
Iradimed Corporation reported that one of its directors received an equity award of 1,026 restricted stock units (RSUs) on December 11, 2025 under the company’s 2023 Equity Incentive Plan. Each RSU converts into one share of common stock when it vests, so this grant represents the right to receive the same number of common shares in the future.
The RSUs vest in two equal annual installments beginning on December 11, 2026, aligning the director’s compensation with longer-term company performance. After this grant, the director beneficially owns 1,932 RSUs, all held as a direct ownership interest.
Iradimed Corporation director Monty K. Allen reported an equity award of derivative securities. On December 11, 2025, he received 1,026 restricted stock units (RSUs) under Iradimed Corporation's 2023 Equity Incentive Plan.
The RSUs convert into common stock on a one-for-one basis. They vest in two equal annual installments beginning on December 11, 2026, and upon each vesting date he will receive one share of common stock for each vested RSU. Following this grant, he beneficially owns 1,932 RSUs directly.
Iradimed Corporation reported an insider equity transaction by an officer serving as Chief Commercial Officer. On December 11, 2025, the officer converted 996 restricted stock units into common stock and disposed of 309 shares at $97.38 per share, resulting in 687 shares of common stock held directly afterward.
The restricted stock units were granted under Iradimed’s 2023 Equity Incentive Plan and convert into common stock on a one-for-one basis. They vest in three equal annual installments beginning on December 11, 2025. Following this activity, the officer beneficially owned 1,994 restricted stock units in addition to the directly held common stock.
Iradimed Corporation director Hilda Scharen-Guivel reported acquiring 905 shares of common stock through the conversion of restricted stock units. The transaction on December 11, 2025 is coded "M", indicating an exercise or conversion of derivative securities, and increased her directly held common stock to 8,598 shares. A related entry in the derivative table shows 905 restricted stock units converting into 905 common shares at an exercise price of $0, leaving 906 restricted stock units beneficially owned. The restricted stock units were granted under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning on December 11, 2025, with shares of common stock delivered as each installment vests.
Iradimed Corporation reported an insider equity transaction by director James B. Hawkins. On December 11, 2025, 905 shares of common stock were acquired following the conversion of restricted stock units, at an exercise price of $0. After this transaction, Hawkins directly beneficially owns 29,647 shares of Iradimed common stock.
The derivative position involved 905 restricted stock units that converted into an equal number of common shares on a one-for-one basis. These units were originally granted on December 11, 2024 under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning on December 11, 2025. Following the reported transaction, 906 restricted stock units remain beneficially owned.
Iradimed Corporation’s chief financial officer, John Glenn, reported several personal stock transactions in the company’s common shares on December 11, 2025. He sold 14,468 shares at a weighted average price of $97.26 in multiple trades and an additional 532 shares at $98.09, as part of his ongoing equity activity.
On the same date, 1,812 restricted stock units (RSUs) converted into common stock on a one‑for‑one basis, and 714 shares were withheld at $97.38 to cover tax obligations, leaving him with 8,460 shares of common stock held directly. He also beneficially owns 3,624 RSUs granted under Iradimed’s 2023 Equity Incentive Plan, which vest in three equal annual installments beginning on December 11, 2025.
Iradimed Corporation director Monty K. Allen reported converting 905 restricted stock units into shares of common stock on December 11, 2025, and now directly holds 22,000 shares.
The restricted stock units were granted on December 11, 2024 under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning December 11, 2025; after this transaction, 906 restricted stock units remain, each convertible into one share of common stock upon vesting.
Iradimed Corporation director James B. Hawkins reported the vesting and conversion of restricted stock units into common stock. On December 7, 2025, 1,197 restricted stock units converted into 1,197 shares of Iradimed common stock at an exercise price of $0, reflecting a standard equity grant vesting.
These units were granted on December 7, 2023 under Iradimed's 2023 Equity Incentive Plan and vest in two equal annual installments beginning December 7, 2024. Following this transaction, Hawkins beneficially owns 31,742 shares of Iradimed common stock directly.
IRADIMED Corporation (IRMD) CEO, president, chairman and director Roger E. Susi reported insider sales of common stock on 11/24/2025. Through the Phillip Susi 2008 Dynasty Trust, he sold a total of 5,000 shares in three transactions: 556 shares at a weighted average price of $89.67, 3,558 shares at $90.31, and 886 shares at $91.01, all coded as open market sales.
These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. After the reported transactions, the Phillip Susi 2008 Dynasty Trust beneficially owns 2,307,500 shares, with additional indirect holdings reported through other trusts.
IRADIMED CORP director reports open-market stock sales. A reporting person serving as a director of IRADIMED CORP (ticker IRMD) disclosed several open-market sales of common stock on 11/20/2025. The transactions, all coded as sales, totaled 3,000 shares at prices ranging from $88.00 to $88.50 per share. After these trades, the director beneficially owned 30,545 shares of IRADIMED common stock in direct ownership. This filing is a routine Form 4 disclosure of insider trading activity and does not describe any company-level operational or financial changes.
IRADIMED Corporation (IRMD) CEO Roger E. Susi, who is also a director, chairman and 10% owner, reported indirect sales of company common stock on 11/18/2025. A trust for his benefit, the Phillip Susi 2008 Dynasty Trust, sold 3,184 shares at a weighted average price of $85.29 and 1,816 shares at a weighted average price of $86.12, in transactions coded as open-market sales. These trades were made under a Rule 10b5-1 trading plan adopted on June 16, 2025. After the reported transactions, indirect beneficial holdings remain in multiple trusts, including over two million shares held through the Phillip Susi 2008 Dynasty Trust.
IRADIMED CORP (IRMD) reported an insider transaction on Form 4 by CEO, President, Chairman and Director Roger E. Susi, who is also a 10% owner. On 11/10/2025, he reported two open-market sales of common stock coded “S”.
He sold 2,252 shares at a weighted average price of $84.59 (individual trades ranged from $84.27 to $85.01) and 2,748 shares at a weighted average price of $85.77 (range $85.29 to $86.09). The sales were effected under a Rule 10b5-1 trading plan adopted on June 16, 2025.
Following these transactions, reported indirect holdings include 2,317,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, as disclosed.
IRADIMED CORP (IRMD) filed a Form 4 reporting an insider sale. The company’s Chief Financial Officer sold 10,651 shares of common stock on 11/10/2025, coded “S” for an open-market sale, at a weighted average price of $84.5143. Following the transaction, the reporting person directly holds 2,500 shares. The sale was executed in multiple trades within a price range of $84.25 to $85.18, with the weighted average provided; full trade details are available upon request.
IRADIMED Corp (IRMD) CEO, President, Chairman and Director Roger E. Susi reported open-market sales of common stock on November 3, 2025.
The filing lists six tranches by an indirect holder, the Phillip Susi 2008 Dynasty Trust, including 1,618 shares at a weighted average price of $83.85, 1,335 shares at $83.22, 900 shares at $81.71, 601 shares at $81.28, 446 shares at $79.82, and 100 shares at $84.60. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
Following the reported transactions, the filing shows 2,322,500 shares held indirectly by the Phillip Susi 2008 Dynasty Trust, 162,950 shares held indirectly by the Roger E. Susi Revocable Trust, and 2,062,500 shares held indirectly by the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership of certain securities except to the extent of pecuniary interest.
IRADIMED (IRMD) insider activity: CEO/President/Chairman and 10% owner Roger E. Susi filed a Form 4 reporting open‑market sales on 10/27/2025 pursuant to a Rule 10b5‑1 trading plan adopted on June 16, 2025.
The filing shows three sales by an indirect holder: 4,242 shares at a weighted average price of $77.56, 700 shares at $78.33, and 58 shares at $79.12. Following these transactions, 2,327,500 shares were beneficially owned indirectly by the Phillip Susi 2008 Dynasty Trust. Additional indirect holdings listed include 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, with a stated disclaimer of beneficial ownership except to the extent of pecuniary interest.
IRADIMED Corp (IRMD) insider Roger E. Susi (CEO, President, Chairman, Director, 10% owner) reported open-market sales totaling 5,000 shares of common stock on 10/21/2025, executed under a Rule 10b5-1 trading plan adopted on June 16, 2025.
The filing shows two trades: 3,577 shares at a weighted average price of $74.58 (individual trades ranged $74.17–$75.07) and 1,423 shares at a weighted average price of $75.41 (ranged $75.22–$75.51).
Following the transactions, the report lists 2,332,500 shares indirectly held by the Phillip Susi 2008 Dynasty Trust, 162,950 shares indirectly held by the Roger E. Susi Revocable Trust, and 2,062,500 shares indirectly held by the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
IRADIMED Corporation (IRMD) director reported RSU vesting and conversion. On 10/14/2025, 1,767 restricted stock units converted into 1,767 shares of common stock at $0 (Transaction Code M). Following the transaction, the director directly holds 6,496 shares.
The RSUs were granted on 10/14/2022 under the 2014 Equity Incentive Plan and vest in three equal annual installments beginning 10/14/2023, delivering one share for each unit that vests.
IRadimed Corp (IRMD) CEO, President and Chairman Roger E. Susi reported insider sales on 10/13/2025 under a Rule 10b5-1 trading plan adopted on June 16, 2025. The transactions totaled 5,000 shares across three trades: 3,227 shares at a weighted average $72.16 (range $71.65–$72.50), 1,746 shares at $73.37 (range $72.93–$73.86), and 27 shares at $74.07 (range $74.05–$74.15).
Following these sales, indirect beneficial ownership was reported as 2,337,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust.
Roger E. Susi, who serves as CEO, President, Chairman and is reported as a 10% owner of Iradimed Corp (IRMD), reported sales of company common stock on 10/06/2025 under a Rule 10b5-1 trading plan adopted 6/16/2025. The Form 4 shows a sale of 4,800 shares at a weighted average price of $71.70 and a separate sale of 200 shares at $72.27, for a total of 5,000 shares disposed. The filing also discloses substantial indirect holdings: 2,342,700 shares indirectly held via a trust and other related trusts holding large positions. The reporting person disclaims beneficial ownership of certain shares except for pecuniary interest.
Joe E. Kiani, a director of Iradimed Corporation (IRMD), received a grant of 2,095 restricted stock units (RSUs) on 09/23/2025 under the companys 2023 Equity Incentive Plan. Each RSU represents a contingent right to one share of common stock and the reporting person is shown as directly owning 2,095 shares following the transaction. The RSUs carry a $0 price and vest in three equal annual installments beginning on 09/23/2026, at which time vested units will convert into an equivalent number of common shares. The Form 4 is signed by Joe E. Kiani on 09/25/2025.
Roger E. Susi, CEO, President and Chairman of IRADIMED CORP (IRMD) reported a sale of 5,000 shares of the company on 09/23/2025 under a Rule 10b5-1 trading plan adopted on 06/16/2025. The weighted average sale price was $71.2581, with individual trade prices ranging from $70.81 to $71.61. After the transaction the filing reports total beneficial ownership of 2,352,500 shares, held indirectly through family and revocable trusts; two other trust positions of 162,950 and 2,062,500 shares are disclosed. The reporting person disclaims beneficial ownership except to the extent of pecuniary interest. The Form 4 is signed and dated 09/24/2025.
Roger E. Susi, CEO, President and Chairman of IRADIMED CORP (IRMD), reported sales of common stock on 09/17/2025 under a Rule 10b5-1 trading plan adopted 06/16/2025. The filing shows 3,454 shares sold at a weighted average price of $71.0016 and 1,546 shares sold at a weighted average price of $71.8808, executed in multiple trades with price ranges disclosed. After these dispositions, aggregate beneficial ownership reported across related trusts and accounts totals 2,062,500 shares directly and 2,359,046/2,357,500 shares indirectly as stated, with a disclaimer limiting claimed beneficial ownership. The form is signed 09/18/2025.